RBC Transfusion Thresholds: Clinical Context, Availability and the Oxygen-Delivery Question
The 2026 AABB review of major advances in transfusion medicine brings together evidence showing that RBC transfusion cannot be reduced to one universal hemoglobin threshold. Clinical context changes the risk-benefit balance, product availability can limit treatment in practice, and similar hematocrit responses do not necessarily describe the whole biological function of an RBC product.
1. There is no single RBC transfusion threshold for every clinical situation
The updated Cochrane review summarized by AABB included 61 adult randomized trials with 27,639 patients and 8 pediatric trials with 2,764 patients.
Restrictive RBC transfusion did not increase 30-day mortality in most clinical contexts, but the review identifies important population-specific exceptions.
Hemoglobin concentration is important, but its clinical meaning depends on the patient and the physiological context.
2. Acute myocardial infarction changes the transfusion logic
The review highlights AABB, ACC/AHA and Canadian cardiovascular guidance suggesting a more liberal RBC transfusion strategy for patients with acute myocardial infarction.
The point is not that more transfusion is always better. The point is that the same hemoglobin concentration does not represent the same physiological risk in every patient.
In myocardial ischemia, the balance between oxygen supply and oxygen demand becomes particularly important.
3. More hemoglobin is also not automatically better
The TOP trial evaluated postoperative RBC transfusion strategies in 1,424 veterans with high baseline cardiac risk and postoperative anemia following major noncardiac surgery.
Non-myocardial-infarction cardiac complications were lower in the liberal group: 5.9% vs 9.9%, RR 0.59.
So the evidence does not support a simple rule that higher Hb is always better or that a lower transfusion threshold is always better.
The clinically relevant question remains: which patient, which condition and which physiological deficit are we trying to correct?
4. RBC availability can determine whether a product can actually be used
The BORN trial randomized extremely low-gestational-age neonates to RBC transfusions from adult donors or cord blood.
A therapeutic product may have useful biological characteristics, but it must still be available, stored, processed, tested, transported and ready when the patient requires treatment.
Availability → deployment → treatment → physiological response
For emergency and time-sensitive medicine, availability becomes part of effective therapeutic performance.
5. Comparable hematocrit does not necessarily mean identical biological performance
In the BORN trial, hematocrit increments and safety profiles were comparable between cord-blood-derived and adult-donor RBC groups.
At the same time, cord-blood RBCs are enriched with fetal hemoglobin, and the per-protocol analysis reported differences in severe or treatment-requiring retinopathy and moderate/severe bronchopulmonary dysplasia. The review states that maintaining higher hemoglobin F percentages may improve outcomes but requires further study.
Hematocrit describes red-cell volume. It does not describe every biological property of the cells carrying oxygen.
Different RBC populations may produce similar hematocrit increments while differing in hemoglobin characteristics, oxygen affinity, cellular age, deformability, metabolism and oxygen-unloading behavior.
6. Transfusion medicine is increasingly becoming function-specific
The review also describes treatment strategies designed around more specific biological functions. In cardiac surgery, the FARES-II trial compared four-factor prothrombin complex concentrate with plasma.
But the same principle was not universally superior. In severe trauma, early fibrinogen concentrate plus 4F-PCC did not reduce allogeneic blood-product use compared with frozen plasma.
When a biological function can be identified, medicine can ask whether that function can be delivered more precisely. The answer remains patient- and context-specific.
What this review shows
1. Hemoglobin threshold is not universal. The clinical effect of restrictive versus liberal RBC transfusion changes across patient populations.
2. Clinical context matters. Acute myocardial infarction, gastrointestinal bleeding, neurocritical illness and postoperative cardiac risk do not produce identical transfusion requirements.
3. Availability matters. Shelf life, volume, processing and testing can limit access to an RBC product even when the product has useful biological characteristics.
4. Laboratory quantity is not necessarily equivalent to biological function. Comparable hematocrit increments do not demonstrate that biologically different RBC populations perform identically.
5. Transfusion medicine is becoming increasingly function-specific. The appropriate treatment depends on the biological function that needs to be supported or restored, the patient and the clinical situation.
BHOC research perspective
We believe these findings support a broader shift toward function-oriented treatment.
The therapeutic objective should not be simply to increase a laboratory value. The objective should be to identify which physiological function is compromised and to support or restore that function in the right patient, at the right time, in a controlled manner and in the appropriate clinical context.
For oxygen therapeutics, the relevant function is oxygen delivery.
Hemoglobin concentration and hematocrit remain important measurements, but they do not by themselves describe whether adequate oxygen is actually reaching the tissues.
Oxygen loading → hemoglobin transport → circulation and microcirculation → oxygen unloading → tissue oxygen availability
We therefore believe that treatment should increasingly focus on the compromised physiological function and on restoration of effective physiology, while clinical signs, symptoms and physiological response remain primary markers of the patient's condition.
This becomes especially important in prehospital EMS. In the field there may be neither sufficient time nor the practical possibility to obtain and interpret complete laboratory information before treatment decisions must be made.
The immediate question is therefore not only what is the patient's hemoglobin concentration?
This is consistent with the logic of prehospital emergency medicine, where treatment decisions are frequently driven by the patient's clinical presentation, vital signs, mental status, signs of shock, hypoperfusion and the overall physiological response.
In prehospital EMS, the immediate goal is to support the patient, limit further physiological deterioration and bridge the patient to the hospital as safely as possible for definitive diagnosis and treatment.
The field does not need to solve every biological problem before hospital arrival. It needs to identify the critical physiological failure early enough and support the patient until definitive care becomes available.
For Precision Oxygen Therapeutics, this creates a clear research question:
BHOC and HBOC technologies are relevant to this question because their primary therapeutic purpose is oxygen transport.
The scientific objective is therefore not simply to reproduce an RBC count, hematocrit value or laboratory hemoglobin concentration. It is to determine whether oxygen-delivery function can be supported effectively, rapidly and safely when that function becomes compromised.
Blood is a system. Oxygen delivery is a function.
Primary source
Related BHOC evidence
Explore the Prehospital EMS application context →
© Archil Jaliashvili